Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Nuevo agente antitumoral producido por la actinobacteria marina Micromonospora matsumotoense

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOES20170901001
Publicado:
06/09/2017
Caducidad:
06/09/2018
Resumen:
Un grupo de investigación español especializado en microbiología ha obtenido la patente de una nueva cepa bacteriana de Micromonospora matsumotoense, que puede producirse de forma eficiente mediante la fermentación de un nuevo compuesto citotóxico de la familia de paulomicinas. Específicamente, esta cepa produce la nueva paulomicina G, con actividad citotóxica contra diferentes líneas celulares tumorales. Se trata de un método más sencillo, corto y económico que el proceso de síntesis orgánica. El grupo de investigación busca compañías en las industrias de microbiología y farmacia con el fin de desarrollar aplicaciones de la tecnología bajo acuerdos de licencia.

Details

Tittle:
Novel antitumor agent produced by the deep sea actinobacterium Micromonospora matsumotoense
Summary:
A Spanish research group specialised in microbiology has patented a novel bacterial strain of Micromonospora matsumotoense, which is able to efficiently produce by fermentation a new cytotoxic compound of the family of paulomycins. Specifically, this strain is producing the new paulomycin G, having cytotoxic activity against different tumour cell lines. Companies in microbiology and pharmacy are sought to develop applications of the described invention under license agreements.
Description:
Marine environments are emerging as a source of new natural products of pharmacological importance and coral reefs have revealed themselves as a medium that should be investigated to discover structurally unique natural products with biomedical relevance. Due to the increasing need for new antitumor agents with improved activity, fewer undesirable side effects and greater selectivity compared to the current drugs in use in the fight against cancer, it is necessary the development of new antitumor agents with improved pharmacological properties. It is also necessary to have simple, short and economical methods for obtaining such compounds with antitumor activity.

Researchers from a Spanish university working in microbiology provide a novel bacterial strain of Micromonospora matsumotoense, isolated during an oceanographic expedition to the submarine Avilés Canyon, which is able to efficiently produce by fermentation a new cytotoxic compound of the family of paulomycins. Specifically, this strain is producing the new paulomycin G, which has cytotoxic activity against different tumour cell lines. It is also the first member of the paulomycin family lacking the paulomycose moiety.

The present invention thus relates to a bacterial strain of Micromonospora matsumotoense, to a supernatant or extract of a culture of such bacterial strain, to the use of the bacterial strain for the production of certain paulomycin, to a process for obtaining said paulomycin, to the Markush formulation of the new paulomycin G, and to a pharmaceutical or cosmetic composition containing it.

The researchers would like to reach license agreements with companies operating in the clinical microbiology and pharmacy fields with the aim to develop applications of the described technology.
Advantages and Innovations:
The present invention represents a solution to the need for new antitumor compounds. It also represents a solution to the need for simple, short and economic procedures for obtaining said compound with antitumor activity as the method of the invention allows to produce such compound by fermentation with an actinobacteria, rather than by chemical synthesis, which is a more complex, lengthy and costly process. In this regard, in biotechnological processes involving obtaining structurally complex natural products, such in the case of paulomycins, the production by fermentation using the producing microorganism is the preferred method because it is simpler, shorter and cheaper than the organic synthesis procedure.
So far, all known paulomycin compounds have only been produced by Streptomyces, thus, paulomycin G is the first member of the family produced by a Micromonospora species.

Since paulomycin G is the smallest member of the family (minimal paulomycin), the unique member of the family lacking the paulomycose moiety, it might be useful for future paulomycin biosynthesis research or as a core structure in the generation of novel derivatives through combinatorial biosynthesis.
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
Spanish patent applied.

Partner sought

Type and Role of Partner Sought:
Type of partner sought: industry.

Specific area of activity of the partner: Clinical microbiology, pharmaceutical industry.

Task to be performed: Under a License agreement, the partner sought will develop applications of the described antitumor agent.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
Spanish

Keywords

Technology Keywords:
06006 Biotecnología industrial
06001003 Citología, cancerología, oncología
06002008 Microbiología
06001015 Productos farmacéuticos / medicamentos